A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

詳細情報 詳細情報について

• CRID

  1360857761036680704

• DOI

  10.1016/j.cct.2020.106170

• ISSN

  15517144

• Web Site

  https://api.elsevier.com/content/article/PII:S1551714420302482?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1551714420302482?httpAccept=text/plain

• データソース種別

  • Crossref